Percent changes are indicate year-over-year increases or decreases for the quarter. The companies are arranged by quarterly net sales or revenue, from highest to lowest.
Medtronic (3rd quarter fiscal year results)
1. Revenue: $7.3 billion (5 percent increase)
2. U.S. revenue: $4.1 billion (4 percent increase)
3. Spine revenue: $657 million (3 percent increase)
4. Pain therapies revenue: $272 million (3 percent decrease)
5. Brain therapies revenue: $518 million (7 percent increase)
1. Net sales: $2.96 billion (18.4 percent increase)
2. Net earnings: $444 million (10.4 percent increase)
3. Medsurg net sales: $1.31 billion (36.2 percent increase)
4. Orthopedics net sales: $1.14 billion (7.4 percent increase)
5. Neurotechnology and spine net sales: $520 million (7.3 percent increase)
1. Net sales: $2.3 billion (0.7 percent decrease)
2. U.S. net sales: $1.3 billion (0.9 percent decrease)
3. Knee net sales: $398 million (2.3 percent increase)
4. Trauma net sales: $642 million (flat)
5. Spine and other net sales: $933 million (3.6 percent decrease)
1. Net sales: $1.98 billion (3.8 percent increase)
2. Net earnings: $299.4 million (175.2 percent increase)
3. Knee sales $702 million (0.2 percent decrease)
4. Hip sales: $475 million (1.7 percent decrease)
5. Spine and CMF: $186 million (32 percent increase)
1. Revenue: $1.1 billion (flat)
2. U.S. revenue: $555 million (1 percent decrease)
3. Sports medicine, trauma and other revenue: $466 million (flat)
4. Joint reconstruction: $396 million (1 percent decrease)
5. Advanced wound management: $280 million (1 percent decrease)
1. Revenue: $250 million (16.2 percent increase)
2. Net income: $12.8 million
3. Operating expenses: $165 million
4. Cash, cash equivalents and short and long term marketable securities: $134 million
5. Operating profit margin: 9.3 percent
1. Sales: $155.8 million (11.9 percent increase)
2. Net income: $28.7 million
3. U.S. sales: $129 million
4. Innovative fusion sales: $81.8 million
5. Disruptive technology: $73.9 million
1. Net sales: $102.7 million (4.1 percent increase)
2. Net loss: $2.3 million
3. Spine sales: $19.3 million (2.3 percent increase)
4. Biologic sales: $15 million (6.3 percent increase)
5. BioStim sales: $44.5 million (8.5 percent increase)
1. Revenue: $61.9 million (9.9 percent increase)
2. Net loss: $10.9 million
3. U.S. revenue: $46.2 million (up 9.5 percent)
4. International revenue: $15.7 million (11.1 percent increase)
5. Adjusted EBITDA: $300,000
More articles on orthopedic implants:
22 spine devices receive FDA 510(k) clearance in April
3 key trends in the global spinal trauma market
Implant survival for minimally invasive vs. open hip surgery: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
